B. C. Cho Et Al. , "KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+Locally Advanced/Metastatic NSCLC," JOURNAL OF THORACIC ONCOLOGY , vol.16, no.3, 2021
Cho, B. C. Et Al. 2021. KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+Locally Advanced/Metastatic NSCLC. JOURNAL OF THORACIC ONCOLOGY , vol.16, no.3 .
Cho, B. C., Wu, Y., Lopes, G., Kudaba, I., Kowalski, D. M., Turna, H. Z., ... De Castro, G.(2021). KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+Locally Advanced/Metastatic NSCLC. JOURNAL OF THORACIC ONCOLOGY , vol.16, no.3.
Cho, B. Et Al. "KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+Locally Advanced/Metastatic NSCLC," JOURNAL OF THORACIC ONCOLOGY , vol.16, no.3, 2021
Cho, B. C. Et Al. "KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+Locally Advanced/Metastatic NSCLC." JOURNAL OF THORACIC ONCOLOGY , vol.16, no.3, 2021
Cho, B. C. Et Al. (2021) . "KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+Locally Advanced/Metastatic NSCLC." JOURNAL OF THORACIC ONCOLOGY , vol.16, no.3.
@article{article, author={B. C. Cho Et Al. }, title={KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+Locally Advanced/Metastatic NSCLC}, journal={JOURNAL OF THORACIC ONCOLOGY}, year=2021}